ReviewMolecular diversity2026
Chemistry, pharmacology and spotlight on the clinical trials of remibrutinib: a first in class, oral Bruton's tyrosine kinase (BTK) inhibitor for chronic spontaneous urticaria.
Shah Alam Khan et al.PubMed ↗Publisher ↗
No numbers read from the abstract.